🔗 Share this article

American leader Donald Trump has announced agreements intended to reduce the price of widely-used obesity treatments, as drug prices become a focus in his government's communication about affordability.

Major Arrangements with Pharmaceutical Companies

Speaking together with drug leaders at the White House, the President unveiled deals with the pharmaceutical company and Novo Nordisk. Patients are scheduled to pay between $245 to $350 each month for weight-loss drugs such as Wegovy and Eli Lilly's medication.

Numerous GLP-1 drugs, used to treat diabetes and obesity, can run over $1,000 monthly without coverage or discounts.

Enhanced Availability to Public Health Programs

The arrangements will expand the company's and the manufacturer's access to the federal health program and Medicaid, the public health plans for older and low-income Americans.

The pharmaceutical firm furthermore said in a statement it would avoid import duties for 36 months as part of the agreement with the Trump administration.

Pricing Details

Approximately one in ten of federal health program beneficiaries will be eligible for expanded access to glucagon-like peptide-1 treatments, and will have to pay only $50, according to high-ranking government officials.

Individuals participating in Medicaid will see a phased implementation contingent upon when states opt in to participate.

TrumpRx Portal Launch

The obesity treatments will be available at lowered costs on the consumer-direct federal platform, a government-run website set to go live by the start of the year.

Via the government website, Wegovy and Eli Lilly's medication will start at $350 monthly typically, and decrease to $250 over a couple of years. The Medicare costs of Novo Nordisk's diabetes drug, Wegovy, Eli Lilly's treatment, and Zepbound will be $245.

More Drug Choices

Along with Novo Nordisk's weight-loss injection, the pharmaceutical firm's weight-loss oral medication, the experimental drug, will be available for $149 for the lowest amount, the manufacturer stated in a statement. The firm's weight-loss medication will cost $299 for a initial dose.

Those costs are contingent upon Food and Drug Administration approval of the drugs.

Insurance Challenges

GLP-1 drugs are frequently not covered by commercial insurers. US legislation forbids Medicare from reimbursing the drugs when used for obesity treatment, although they typically are reimbursed when prescribed for diabetes and heart conditions. Only 13 US states provide reimbursement under Medicaid for slimming reasons.

Health Secretary's Comments

The top health official Robert F Kennedy Jr, speaking at the executive mansion, said the agreements were results of months of discussions with the pharmaceutical company and Novo Nordisk. He called excess weight "the number one driver of persistent health conditions" in the US.

"It will be a life-saving measure to them," the Health Secretary stated.

"It's not a cure-all, this is not a silver bullet," he continued, stressing the significance of eating habit modifications and regular activity.

Background of Pharmaceutical Price Efforts

Starting in summer, Trump has been urging drug companies to lower medication costs. He sent messages to 17 medication manufacturers in the summer, allowing them two months to reply to his demands for reduced rates.

Pfizer was the primary significant medication manufacturer to secure a deal with Trump, reducing costs for selected medicines by nearly 85% on the federal portal. Pfizer additionally agreed to reduce medication prices for the state-federal health plan.

The British-Swedish firm and the German company have also reached deals with the federal leadership in recent weeks.